Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Diabetic Nephropathy | Current Treatment: Physician Insights | US | 2017

Login to access report north_east
Contact sales account_box

Diabetic nephropathy (DN) refers to kidney disease caused by diabetes. DN is a leading cause of chronic kidney disease (CKD), and is associated with high morbidity, mortality, and cost. Use of pharmacotherapy for DN varies by disease severity, physician specialty, and CKD stage. Physicians consider management of DN challenging because current therapies manage only the complications of DN. Currently available therapies have limited efficacy, are unable to treat the underlying disease, and prevent progressive renal decline in patients. Our Current Treatment deep dive content investigates the current prescribing practices for DN and focuses on the various factors driving the these treatment decisions.

Questions Answered

  • Do treatment decisions for DN differ based on disease progression and the specialty of the treating physician?
  • Which attributes are most important in choosing drugs for the management of DN patients?
  • How do physicians perceive standard of care therapies such as ACE inhibitors or ARBs for DN?
  • What is the level of satisfaction among physicians with currently available DN treatments? What is the level of familiarity and interest in products in the development pipeline?
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
north_east
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
north_east
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
north_east
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east